Home > Healthcare > Pharmaceuticals > Finished Drug Form > Biosimilars Market

Biosimilars Market Share

Report ID: GMI3328
Published Date: Jul 2023
Report Format: PDF

Download Free Sample

Biosimilars Market Share

The competitive landscape of the biosimilars market includes:

prominent enterprises
such as Dr. Reddy’s Laboratories
Sandoz
Coherus Biosciences
Viatris
Bio-Thera Solutions
Pfizer
Apobiologix
Amgen
Teva Pharmaceuticals
Fresenius Kabi
Biocon Ltd
Biocad
Reliance Life Sciences
Intas Pharma
Celltrion
Zydus Cadila
Lupin Pharma, and Samsung Bioepis.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Biosimilars industry size surpassed USD 35 billion in 2022 and is set to expand at 13% CAGR from 2023 to 2032 owing to the high prevalence of chronic diseases globally

Biosimilars market size from the hematology application segment is estimated to generate more than USD 52 billion by the end of 2032 owing to the development of monoclonal antibodies for the treatment of blood diseases.

North America biosimilars industry size is projected to be worth more than USD 26.5 billion by the end of 2032 owing to increasing demand as viable replacements for expensive biologics in addition to the supportive regulatory frameworks in the region.

Some of the prominent enterprises operating in the biosimilars industry are Dr. Reddy’s Laboratories, Sandoz, Coherus Biosciences, Viatris, Bio-Thera Solutions, Pfizer, Apobiologix, Amgen Inc., Teva Pharmaceuticals, Fresenius Kabi, Biocon Ltd., Biocad, Reliance Life Sciences, and Intas Pharma